BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yoshiji H, Noguchi R, Kojima H, Ikenaka Y, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Yamazaki M, Toyohara M, Mitoro A, Fukui H. Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. World J Gastroenterol 2006; 12(42): 6786-6791 [PMID: 17106926 DOI: 10.3748/wjg.v12.i42.6786]
URL: https://www.wjgnet.com/1007-9327/full/v12/i42/6786.htm
Number Citing Articles
1
Hamid Namazi. ACE Inhibitors: A Novel Treatment for NeurofibromaAnnals of Surgical Oncology 2008; 15(5): 1538 doi: 10.1245/s10434-007-9737-5
2
Hala M. Raslan, Khalda S. Amr, Yasser A. Elhosary, Wafaa M. Ezzat, Nour A. Abdullah, Hassan E. El-Batae. Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infectionTransactions of the Royal Society of Tropical Medicine and Hygiene 2011; 105(7): 396 doi: 10.1016/j.trstmh.2011.03.005
3
Josephine A. Grace, Chandana B. Herath, Kai Yan Mak, Louise M. Burrell, Peter W. Angus. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic optionsClinical Science 2012; 123(4): 225 doi: 10.1042/CS20120030
4
Puneeta Tandon, Juan G. Abraldes, Annalisa Berzigotti, Juan Carlos Garcia-Pagan, Jaime Bosch. Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysisJournal of Hepatology 2010; 53(2): 273 doi: 10.1016/j.jhep.2010.03.013
5
Montserrat Moreno, Ramon Bataller. Cytokines and Renin-Angiotensin System Signaling in Hepatic FibrosisClinics in Liver Disease 2008; 12(4): 825 doi: 10.1016/j.cld.2008.07.013
6
Hamid Namazi. Effect of intraurethral captopril gel on the recurrence of urethral stricture after direct vision internal urethrotomy: A novel molecular mechanismInternational Journal of Urology 2008; 15(6): 562 doi: 10.1111/j.1442-2042.2008.02072.x
7
J. Macías, M. M. Viloria, A. Rivero, I. Santos, M. Márquez, J. Portilla, F. Di Lello, A. Camacho, J. Sanz-Sanz, G. Ojeda, R. Mata, J. Gómez-Mateos, J. A. Pineda. Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapyEuropean Journal of Clinical Microbiology & Infectious Diseases 2012; 31(8): 2083 doi: 10.1007/s10096-012-1546-5
8
Yavuz Beyazit, Mehmet İbis, Tugrul Purnak, Turan Turhan, Murat Kekilli, Mevlut Kurt, Abdurrahim Sayilir, İbrahim Koral Onal, Nesrin Turhan, Adnan Tas, Seyfettin Köklü, İbrahim C. Haznedaroglu. Elevated Levels of Circulating Angiotensin Converting Enzyme in Patients with Hepatoportal SclerosisDigestive Diseases and Sciences 2011; 56(7): 2160 doi: 10.1007/s10620-011-1580-7
9
Amanda M Murphy, Alison L Wong, Michael Bezuhly. Modulation of angiotensin II signaling in the prevention of fibrosisFibrogenesis & Tissue Repair 2015; 8(1) doi: 10.1186/s13069-015-0023-z
10
Hitoshi Yoshiji. The Liver in Systemic Diseases2016; : 149 doi: 10.1007/978-4-431-55790-6_8
11
Kathleen E. Corey, Nirali Shah, Joseph Misdraji, Barham K. Abu Dayyeh, Hui Zheng, Atul K. Bhan, Raymond T. Chung. The effect of angiotensin‐blocking agents on liver fibrosis in patients with hepatitis CLiver International 2009; 29(5): 748 doi: 10.1111/j.1478-3231.2009.01973.x
12
Qianqian Zhu, Na Li, Fang Li, Zhihua Zhou, Qunying Han, Yi Lv, Jiao Sang, Zhengwen Liu. Therapeutic effect of renin angiotensin system inhibitors on liver fibrosisJournal of the Renin-Angiotensin-Aldosterone System 2016; 17(1) doi: 10.1177/1470320316628717
13
Pablo Muriel, Yadira Rivera‐Espinoza. Beneficial drugs for liver diseasesJournal of Applied Toxicology 2008; 28(2): 93 doi: 10.1002/jat.1310
14
Fiona J. Warner, Harinda Rajapaksha, Nicholas Shackel, Chandana B. Herath. ACE2: from protection of liver disease to propagation of COVID-19Clinical Science 2020; 134(23): 3137 doi: 10.1042/CS20201268
15
Alessandro Siani. Pharmacological Treatment of Fibrosis: a Systematic Review of Clinical TrialsSN Comprehensive Clinical Medicine 2020; 2(5): 531 doi: 10.1007/s42399-020-00292-2
16
Yue-Cheng Guo, Lun-Gen Lu. Antihepatic Fibrosis Drugs in Clinical TrialsJournal of Clinical and Translational Hepatology 2020; 8(4): 1 doi: 10.14218/JCTH.2020.00023
17
Zuo-Wei Ning, Xiao-Ying Luo, Guo-Zhen Wang, Yang Li, Miao-Xia Pan, Ren-Qiang Yang, Xu-Guang Ling, Shan Huang, Xiao-Xin Ma, Si-Yi Jin, Dan Wang, Xu Li. MicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome/IL-1β Axis via Targeting Smad7 and Spry1Antioxidants & Redox Signaling 2017; 27(1): 1 doi: 10.1089/ars.2016.6669